Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05945147
Other study ID # 66661
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 1, 2024
Est. completion date May 31, 2024

Study information

Verified date February 2024
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).


Description:

Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are: 1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial. 2. Evaluate whether participants can adhere to study procedures. 3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion. 4. Gather preliminary data on clinically-relevant outcomes for CRPS.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 31, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility - Age 18 to 65 years - Meets the International Association for the Study of Pain (IASP) diagnostic criteria for complex regional pain syndrome (CRPS) - Primary complaint of CRPS-attributable pain for =3 months - Average pain intensity of =3/10 over the last month - Can read and comprehend English-language questionnaires - Can receive text messages by phone - Can identify a responsible adult who can provide transportation to and from infusion site for 5 consecutive days (Mon-Fri)

Study Design


Intervention

Drug:
Ketamine
An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Midazolam
A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
Normal Saline
An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days

Locations

Country Name City State
United States Stanford University Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and proportion of patients who can undergo the steps of recruitment, informed consent, enrollment, and randomization Out of all patients identified as potentially eligible for the study based on chart review, we will measure the number and proportion who can undergo the steps of recruitment, informed consent, enrollment, and randomization during a 2-month period. 2 months after the study opens for enrollment
Primary Number and proportion of randomized participants who remain in the study until the last follow-up timepoint Out of all patients who were randomized to a treatment group, we will measure the number and proportion who remain in the study until their last follow-up timepoint. 8 weeks after receiving intervention
Primary Change in participant masking Participants will be asked to guess their assigned treatment in a forced binary choice and to rate their level of confidence on a scale from 0 to 100%. Daily during intervention administration (5 days), and once at 8 weeks after receiving intervention
Primary Change in participant masking Participants will be asked to guess their assigned treatment in a forced binary choice and to rate their level of confidence on a scale from 0 to 100%. During intervention administration
Primary Change in investigator masking Investigators administering and monitoring the drug infusions will be asked to guess the participant's assigned treatment in a forced binary choice and to rate their level of confidence on a scale from 0 to 100%. 8 weeks after receiving intervention
Primary Change in investigator masking Investigators administering and monitoring the drug infusions will be asked to guess the participant's assigned treatment in a forced binary choice and to rate their level of confidence on a scale from 0 to 100%. During intervention administration
Primary Number and types of adverse events Adverse events will be elicited from the participant in a brief, open-ended structured interview. 8 weeks after receiving intervention
Secondary Pain intensity A numerical rating scale ranging from 0 (no pain) to 10 (worst pain imaginable) over the past 24 hours will be used to assess pain intensity. Baseline, daily during treatment (5 days), and daily for 8 weeks after treatment
Secondary Treatment expectancies The 6-item Healing Encounters and Attitudes Lists (HEAL) Short Form for Treatment Expectancy will be used to assess self-reported expectations about the study treatment. Participants are asked to rate their agreement with brief statements such as, "This treatment will be successful" and "I am confident in this treatment". Baseline, and daily during treatment (5 days)
Secondary Pain interference The 6-item PROMIS Pain Interference Short Form assesses the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("Very Much"). Raw score totals are converted to standardized T-scores, with a higher T-score representing greater pain interference. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Physical function The 6-item PROMIS Physical Function Short Form assesses the ability to carry out physical tasks and activities in one's daily life. Items are self-rated on a 5-point scale ranging from 1 ("Unable to do") to 5 ("Without any difficulty"). Raw score totals are converted to standardized T-scores, with a higher T-score representing better physical function. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Depression (PROMIS) The 6-item PROMIS Depression Short Form assesses the severity of depressive symptoms experienced by an individual. Items are self-rated on a 5-point scale ranging from 1 ("Never") to 5 ("Always"). Raw score totals are converted to standardized T-scores, with a higher T-score representing greater depression symptom severity. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Depression (PHQ-9) The 9-item PHQ-9 will be used as an additional indicator for changes in depression symptom severity, and to monitor for any risk of acute suicidality during the trial (item #9: "Thoughts that you would be better off dead, or of hurting yourself"). Items are self-rated on a 4-point scale ranging from 0 ("Not at all") to 3 ("Nearly every day"). Higher total scores indicate greater depression symptom severity. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Anxiety The 6-item PROMIS Anxiety Short Form assesses the severity of anxiety symptoms experienced by an individual. Items are self-rated on a 5-point scale ranging from 1 ("Never") to 5 ("Always"). Raw score totals are converted to standardized T-scores, with a higher T-score representing greater anxiety symptom severity. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Sleep disturbance The 6-item PROMIS Sleep Disturbance Short Form assesses the severity of sleep-related issues, such as trouble falling asleep, staying asleep, and experiencing non-restorative sleep. Items are self-rated on a 5-point scale ranging from 1 ("Not at all") to 5 ("Very Much"). Raw score totals are converted to standardized T-scores, with a higher T-score representing greater sleep disturbance. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Pain catastrophizing The 13-item Pain Catastrophizing Scale assesses the extent to which an individual engages in magnifying, rumination, and helplessness thoughts related to their pain experience. Items are self-rated on a 5-point scale ranging from 0 ("Not at all") to 4 ("All the time"). Higher total scores indicates higher levels of pain catastrophizing. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Chronic pain acceptance The 8-item Chronic Pain Acceptance Questionnaire assesses one's level of acceptance and willingness to engage in valued activities despite the presence of chronic pain. Items are self-rated on a 7-point scale ranging from 0 ("Never true") to 6 ("Always true"). Higher total scores indicate greater levels of chronic pain acceptance. Baseline, and weekly for 8 weeks after the end of treatment
Secondary Patient global impression of change The Patient Global Impression of Change scale assesses the patient's perception of change in their overall health status resulting from a specific treatment. The single-item scale is self-rated on a 7-point scale ranging from 1 ("Very much improved") to 7 ("Very much worse"). Weekly for 8 weeks after the end of treatment
Secondary Number of painful body regions The CHOIR Body Map is a visual tool that allows individuals to indicate the location(s) of their pain on a human body outline. Baseline, and weekly for 8 weeks after the end of treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04066933 - Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M
Completed NCT04597866 - Treatment of Complex Regional Pain Syndrome, a Long-term Follow-up
Completed NCT04060875 - Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
Not yet recruiting NCT06453447 - Prednisone for CRPS in Distal Radius Fracture N/A
Terminated NCT01954888 - Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain N/A
Terminated NCT00689585 - Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) Phase 2
Recruiting NCT00377468 - Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Phase 2
Recruiting NCT05787119 - Benefit of Augmented Reality Mirror Therapy in Addition to Conventional Management in Complex Regional Pain Syndrome of the Upper Extremity N/A
Recruiting NCT05523934 - Retrospective Analysis of capsaïcin Patch in Complex Regional Pain Syndrome
Recruiting NCT04732325 - Sensory Testing of Multiple Forms of Spinal Cord Stimulation for Pain N/A
Completed NCT03174249 - Exposure Therapy Combined With Cortical Interventions for CRPS-II N/A
Recruiting NCT06033456 - Combining Stellate Ganglion and T2 and T3 Radiofrequency Ablation on Post-mastectomy Complex Regional Pain Syndrome N/A
Recruiting NCT04144972 - Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain N/A
Completed NCT02490436 - Novel Treatment Option for Neuropathic Pain Phase 2
Withdrawn NCT03316066 - Comparison of Volumes of Local Anesthetics on the Efficiency and Safety of Stellate Ganglion Block for CRPS of the Arm N/A
Recruiting NCT05491499 - Assessing the Impact of Exercise Based Intensive Interdisciplinary Pain Treatment (IIPT) on Endogenous Pain Modulation in Youth With Chronic Pain Syndromes
Completed NCT03291197 - Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome Phase 4
Recruiting NCT05034835 - Impact of Compression Garments on Pain in Patients With Complex Regional Pain Syndrome of the Upper Limbs. N/A
Completed NCT05696587 - Physical and Psychological Changes in CRPS Patients Undergoing Multimodal Rehabilitation N/A
Recruiting NCT02957240 - Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures N/A